Online inquiry

IVTScrip™ mRNA-Anti-CD40, 4D11(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ531MR)

This product GTTS-WQ531MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CD40 gene. The antibody can be applied in Psoriasis, Organ transplant immunological rejection suppression research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001250.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 958
UniProt ID P25942
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD40, 4D11(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ531MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2675MR IVTScrip™ mRNA-Anti-SOST, AMG 785 (Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG 785
GTTS-WQ5495MR IVTScrip™ mRNA-Anti-IL6, CDP 6038(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CDP 6038
GTTS-WQ1653MR IVTScrip™ mRNA-Anti-GP6, ACT-017(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ACT-017
GTTS-WQ692MR IVTScrip™ mRNA-Anti-IL17A&TNF, A-1230717(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA A-1230717
GTTS-WQ812MR IVTScrip™ mRNA-Anti-LRRC15, ABBV-085(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABBV-085
GTTS-WQ11182MR IVTScrip™ mRNA-Anti-TNFRSF4, MEDI0562(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MEDI0562
GTTS-WQ9444MR IVTScrip™ mRNA-Anti-KIR3DL2, IPH4102(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IPH4102
GTTS-WQ2124MR IVTScrip™ mRNA-Anti-CGRP, ALD-403(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ALD-403
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW